Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis PL McCarthy, SA Holstein, MT Petrucci, PG Richardson, C Hulin, P Tosi, ... Journal of Clinical Oncology 35 (29), 3279, 2017 | 679 | 2017 |
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial PM Voorhees, JL Kaufman, J Laubach, DW Sborov, B Reeves, ... Blood, The Journal of the American Society of Hematology 136 (8), 936-945, 2020 | 600 | 2020 |
Isoprenoids: remarkable diversity of form and function SA Holstein, RJ Hohl Lipids 39 (4), 293-309, 2004 | 286 | 2004 |
Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience SA Holstein, PL McCarthy Drugs 77, 505-520, 2017 | 230 | 2017 |
Multiple myeloma, version 3.2017, NCCN clinical practice guidelines in oncology SK Kumar, NS Callander, M Alsina, D Atanackovic, JS Biermann, ... Journal of the National Comprehensive Cancer Network 15 (2), 230-269, 2017 | 225 | 2017 |
American society of blood and marrow transplantation, european society of blood and marrow transplantation, blood and marrow transplant clinical trials network, and … S Giralt, L Garderet, B Durie, G Cook, G Gahrton, B Bruno, P Hari, ... Biology of Blood and Marrow Transplantation 21 (12), 2039-2051, 2015 | 205 | 2015 |
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group P Moreau, SK Kumar, J San Miguel, F Davies, E Zamagni, N Bahlis, ... The Lancet Oncology 22 (3), e105-e118, 2021 | 194 | 2021 |
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a … SA Holstein, SH Jung, PG Richardson, CC Hofmeister, DD Hurd, ... The Lancet Haematology 4 (9), e431-e442, 2017 | 162 | 2017 |
NCCN guidelines insights: multiple myeloma, version 3.2018 SK Kumar, NS Callander, M Alsina, D Atanackovic, JS Biermann, ... Journal of the National Comprehensive Cancer Network 16 (1), 11-20, 2018 | 151 | 2018 |
CAR T‐cell therapy in hematologic malignancies: a voyage in progress SA Holstein, MA Lunning Clinical Pharmacology & Therapeutics 107 (1), 112-122, 2020 | 135 | 2020 |
Phosphonate and bisphosphonate analogues of farnesyl pyrophosphate as potential inhibitors of farnesyl protein transferase SA Holstein, DM Cermak, DF Wiemer, K Lewis, RJ Hohl Bioorganic & medicinal chemistry 6 (6), 687-694, 1998 | 135 | 1998 |
Consequences of mevalonate depletion: differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, and RhoB SA Holstein, CL Wohlford-Lenane, RJ Hohl Journal of Biological Chemistry 277 (12), 10678-10682, 2002 | 112 | 2002 |
Synergistic interaction of lovastatin and paclitaxel in human cancer cells SA Holstein, RJ Hohl Molecular cancer therapeutics 1 (2), 141-149, 2001 | 105 | 2001 |
Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells H Tong, SA Holstein, RJ Hohl Analytical biochemistry 336 (1), 51-59, 2005 | 98 | 2005 |
Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies SA Holstein, HR Knapp, GH Clamon, DJ Murry, RJ Hohl Cancer chemotherapy and pharmacology 57, 155-164, 2006 | 97 | 2006 |
The role of osteocytes in targeted bone remodeling: a mathematical model JM Graham, BP Ayati, SA Holstein, JA Martin PloS one 8 (5), e63884, 2013 | 94 | 2013 |
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma MA Dimopoulos, AJ Jakubowiak, PL McCarthy, RZ Orlowski, M Attal, ... Blood cancer journal 10 (2), 17, 2020 | 93 | 2020 |
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials LJ Costa, BA Derman, S Bal, S Sidana, S Chhabra, R Silbermann, JC Ye, ... Leukemia 35 (1), 18-30, 2021 | 86 | 2021 |
Interaction of cytosine arabinoside and lovastatin in human leukemia cells SA Holstein, RJ Hohl Leukemia research 25 (8), 651-660, 2001 | 86 | 2001 |
Isoprenoids influence expression of Ras and Ras-related proteins SA Holstein, CL Wohlford-Lenane, RJ Hohl Biochemistry 41 (46), 13698-13704, 2002 | 85 | 2002 |